Next Article in Journal
Changes in the Microbial Composition of the Cecum and Histomorphometric Analysis of Its Epithelium in Broilers Fed with Feed Mixture Containing Fermented Rapeseed Meal
Next Article in Special Issue
The History of Colistin Resistance Mechanisms in Bacteria: Progress and Challenges
Previous Article in Journal
An Oral FMT Capsule as Efficient as an Enema for Microbiota Reconstruction Following Disruption by Antibiotics, as Assessed in an In Vitro Human Gut Model
Previous Article in Special Issue
Genomic Analysis of Antimicrobial Resistance Genotype-to-Phenotype Agreement in Helicobacter pylori
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 9
Issue 2
10.3390/microorganisms9020359
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Diversity and Distribution of Resistance Markers in Pseudomonas aeruginosa International High-Risk Clones

by
Béla Kocsis
*,
Dániel Gulyás
and
Dóra Szabó
Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary
*
Author to whom correspondence should be addressed.
Microorganisms 2021, 9(2), 359; https://doi.org/10.3390/microorganisms9020359
Submission received: 23 January 2021 / Revised: 8 February 2021 / Accepted: 8 February 2021 / Published: 12 February 2021
(This article belongs to the Special Issue Systems Involved in Antimicrobial Resistance and Virulence of Clinically Important Pathogens)
Browse Figure
Versions Notes

Abstract

:
Pseudomonas aeruginosa high-risk clones are disseminated worldwide and they are common causative agents of hospital-acquired infections. In this review, we will summarize available data of high-risk P. aeruginosa clones from confirmed outbreaks and based on whole-genome sequence data. Common feature of high-risk clones is the production of beta-lactamases and among metallo-beta-lactamases NDM, VIM and IMP types are widely disseminated in different sequence types (STs), by contrast FIM type has been reported in ST235 in Italy, whereas GIM type in ST111 in Germany. In the case of ST277, it is most frequently detected in Brazil and it carries a resistome linked to blaSPM. Colistin resistance develops among P. aeruginosa clones in a lesser extent compared to other resistance mechanisms, as ST235 strains remain mainly susceptible to colistin however, some reports described mcr positive P. aeurigonsa ST235. Transferable quinolone resistance determinants are detected in P. aeruginosa high-risk clones and aac(6′)-Ib-cr variant is the most frequently reported as this determinant is incorporated in integrons. Additionally, qnrVC1 was recently detected in ST773 in Hungary and in ST175 in Spain. Continuous monitoring and surveillance programs are mandatory to track high-risk clones and to analyze emergence of novel clones as well as novel resistance determinants.

1. Introduction

Pseudomonas aeruginosa is a Gram-negative ubiquitous rod-shaped bacterium and one of the most common opportunistic human pathogens with the ability of causing a wide range of severe infections, including ventilator-associated pneumonia, otitis externa, burn wound infection, contact lense-related keratitis, and bloodstream infection [1,2,3,4]. Various antibiotic resistance mechanisms can occur in P. aeruginosa that enable it to develop multiresistance, therefore, it can cause difficult to treat infections. P. aeruginosa is a member of the “ESKAPE” group, and this group of pathogens comprises 6 multidrug resistant bacteria that are common nosocomial pathogens [5]. Moreover, infections caused by ESKAPE pathogens are usually associated with significantly high morbidity and mortality rates as limited number of effective antimicrobial agents are available against these pathogens [6,7,8,9].
Recently, the World Health Organization released a priority list for development of novel antibiotics against certain pathogens and carbapenem resistant P. aerigunosa is listed among ‘critical’ category pathogens, as research and development of antibacterial agents are urgently needed [10]. The need for novel antibiotics against P. aeruginosa is seen worldwide, as both intrinsic and acquired resistance mechanisms are detected in this pathogen [7,11,12].
P. aeruginosa exhibits intrinsic resistance to a variety of antibacterial agents due to its unusually decreased outer-membrane permeability as well as by upregulation of efflux pumps [13,14,15]. Furthermore, acquired resistance to beta-lactams and aminoglycosides can develop through acquisition of resistance genes [7,15,16]. The most common resistance to beta-lactams occurs through production of different beta-lactamases, namely AmpC beta-lactamases, extended-spectrum beta-lactamases (ESBLs), and carbapenemases [17,18,19,20]. The most frequently reported beta-lactamases in P. aeuginosa are ESBLs (e.g., PER, GES, VEB enzymes), OXA-type beta-lactamases, and metallo-beta-lactamases (MBLs) namely, IMP, VIM, NDM types [21,22]. Uncommon carbapenem resistance phenotype in P. aeruginosa has been also reported namely, carbapenem resistance with maintained cefalosporin susceptibility [23,24]. Aminoglycoside-modifying enzymes are also commonly detected in P. aeruginosa namely, aacA4, aadA7, aph(3′)-IIb [25,26,27]. Colistin resistance develops in P. aeuginosa either by alterations in two-component regulatory systems (PhoPQ and PmrAB) [28,29,30] or through acquisition of mobile genetic elements (mcr) [31]. Fluoroquinolone resistance develops by accumulation of mutations in gyrase and topoisomerase genes namely, in gyrA, gyrB, parC, and parE [32]. However, transfer of mobile genetic elements, such as integrons, integrative conjugative elements (ICEs), transposons, and plasmids play a role in dissemination of crpP, aac(6′)-Ib-cr, or qnrVC1 fluoroquinolone resistance markers [20,33,34].
Emergence and worldwide dissemination of multidrug-resistant (MDR) P. aeruginosa made it necessary to apply typing methods for analysis of spread of MDR strains. Multilocus sequence typing (MLST) of MDR P. aeruginosa strains is the most common method to identify clones based on sequence type (ST) [35]. According to STs, high-risk clones are identified and their disseminations can be tracked. Additionally, core genome MLST has a higher resolution capacity that can be also applied in surveillance programs [36]. MDR clones are present worldwide and they evolve usually in hospital environments, as these clones are generally selected out in hospitals, due to antibiotic selection pressure and they can survive long-lasting in favorable conditions in hospital environments. Furthermore, genome of P. aeruginosa has a complexity and high variability, therefore P. aeruginosa can acquire and exchange resistance determinants that enables it for survival and dissemination. Thus, persistence of MDR P. aeruginosa empowers these strains for hospital outbreaks worldwide. These MDR P. aeruginosa are referred as international high-risk clones, such as the most frequently reported ST 111, 175, 233, 235, 277, 357, 654, and 773 [12,20,37,38]. In this comparative review, we analyze international high-risk clones based on their linkage and distribution of resistance determinants.

2. ST235

According to all available data, this international high-risk clone is the predominant among sequence types in clinical isolates [37,38,39]. ST235 strains show a wide geographic distribution, as they were isolated in various countries, namely Belgium [40], Portugal [41], Hungary, Serbia [33], Greece, Italy, Croatia, Romania [12,42], Spain [43,44], France [45], Germany [46], Norway (this patient was hospitalized earlier in Cyprus) [47], and also from Korea [48,49], Japan [50], Nigeria [51], Brazil, Philippines, US, Mexico, India [12], Vietnam [52], Malaysia, Thailand [53], Russia, Belarus, and Kazakhstan [54] (Figure 1).
The strains identified in ST235 clone carried various ESBLs, such as blaPER-1 in Serbia, and in Hungary [33], blaPSE-1 in Greece [12], blaBEL-1 in Belgium [40], chromosomally located class I integron (In1076) associated blaGES-6 in Portugal [41], class I integron co-harboring blaGES-1, blaGES-5 in Spain [43]. Various blaOXA variants were found in strains of ST235, the most common one was blaOXA-2, but blaOXA-1, blaOXA-10, blaOXA-11, blaOXA-35, blaOXA-74, blaOXA-17, blaOXA-50, blaOXA-129 were also detected [12,51]. In the US, blaPSE-1 was detected however, in Mexico blaGES-1, blaGES-19, blaGES-9-like, whereas in Brazil, blaCTXM-2 was reported [12]. Additionally, blaKPC-2 was confirmed in samples from Colombia and Nigeria [12,55,56,57].
Vast majority of MBLs in strains of ST235 are IMP variants, namely blaIMP-1, blaIMP-2, blaIMP-4, blaIMP-6, blaIMP-7, blaIMP-10, blaIMP-15, blaIMP-26, blaIMP-31, blaIMP-51 from Malaysia, Korea, Philippines, Japan, Vietnam, and Nigeria [12,46,48,50,51,52,53]. Interestingly, blaIMP-6 and blaIMP-10 genes were reported as incorporated into genomic island (PAGI-16) in South Korea [49]. Among VIM types blaVIM-1, blaVIM-2, blaVIM-4, blaVIM-11, blaVIM-13, blaVIM-47 were reported [12,47,52,53,54,58,59]. Furthermore, blaNDM-1 carrier P. aeruginosa strains were isolated from a patient with acute pyelonephritis in France in 2012, and from a stem cell transplant recipient in Italy in 2013. Both patients were hospitalized previously in Serbia [11,60]. Subsequently, an another blaNDM-1 positive strain was reported in Vietnam in 2016 [52]. Later, in 2019, a blaNDM-1 positive P. aeruginosa was isolated in Italy from a patient who developed sepsis as a consequence of urinary tract infection caused by P. aeruginosa ST235. This strain carried different virulence determinants, including ExoU phospholipase that is an effector of type III secretion system and it is responsible for cytotoxic activity [61].
In P. aeuginosa ST235, a blaFIM-1 MBL gene was described in 2012 in Florence, Italy. FIM-1 beta-lactamase showed approximately 40% identity of amino acid sequence of NDM-type beta-lactamases. The blaFIM-1 was located on chromosome of P. aeuriginosa ST235 and flanked by ISCR19, that explains its insertion into the chromosome. However, mobilization and dissemination of this determinant is unknown. It seems that blaFIM is endemic in Florence, as no distribution in other geographical regions has been recorded, yet [42].
In most cases, aac(6’)-Ib aminoglycoside acetyltransferase was reported in ST235 and it is responsible for resistance to kanamycin, tobramycin, and amikacin [12,51]. Strains of ST235 in Europe usually contained aacA7 that encodes aminoglycoside 6’-N-acetyltransferase and some of them carried aph(6)-Id aminoglycoside O-phosphotransferase or aadA1 adenylyltransferase. In case of plasmid-mediated quinolone resistance determinants, aac(6′)-Ib-cr was first described in P. aeruginosa ST235 in isolates from Serbia and Hungary [33].
Chloramphenicol resistance genes, cmlA7 and catB7 were also described in Hungary, Serbia, and Nigeria [33,52]. In a Nigerian sample, other resistance determinants were also confirmed, fosA for fosfomycin, tetA, tetG for tetracycline, and qnrVC1 for fluoroquinolone resistance [52]. Compared to each other, strains of ST235 were characterized by quite similar resistance patterns however, they showed diversity based on the produced enzyme types and in the linkage to their geographic distribution.
A comprehensive study conducted in Madrid, revealed that MDR P. aeuginosa ST235 causes high mortality rate in patients in invasive infections, especially in patients with chronic respiratory tract infections [62].

3. ST111

This international successful clone is also responsible for numerous MDR P. aeruginosa cases around the world [63]. Reports from various European countries described ST111 in Portugal, Spain, Greece, France, Croatia, [12,64] Czech Republic [65], Sweden, and Norway [47]. (Figure 1) MDR ST111 isolates from Bulgarian hospitals showed a combination of ESBL production (VEB-1 and OXAs) with the lack of OprD carbapenem porin and overexpression of MexXY-OprM efflux pump resulting carbapenem resistance without harboring any encoded MBLs [66]. In The Netherlands, a nationwide emergence of this sequence type was also detected in 2012 [67]. The first full genome sequence of ST111 P. aeruginosa was described in the United Kingdom in 2014 and was deposited in the European Nucleotide Archive with accession number PRJEB4573 [63] (Table 1).
ST111 strains were reported from Colombia [75], India, Venezuela, Canada, and United States [12]. In Columbia, a report detailed detection of co-carriage of blaVIM-2 and blaKPC-2 in a single P. aeruginosa strain that belonged to ST111. This strain was resistant to amikacin, ciprofloxacin, polymyxin, and to all beta-lactams, including carbapenems and aztreonam [75]. In 2015, almost 90 isolates of P. aeruginosa ST111 were analyzed in the United Kingdom. Most tested strains carried blaVIM-2, a few had blaIMP-1 or blaIMP-13, and one presented coexistence of blaVIM-2 and blaIMP-18, whereas another strain presented blaNDM-1 [68].
GIM type metallo-beta-lactamase was reported as an integron-encoded gene [76]. This MBL type shares 40% amino acid sequence similarity to IMP type MBLs. So far, blaGIM was detected only in P. aeruginosa ST111, and seems endemic in Germany [77].
Apart from blaVEB-1, other ESBLs, such as blaPSE-1 and blaGES-7 were present in ST111 and numerous types of oxacillinases, such as blaOXA-2, blaOXA-9, blaOXA-10, blaOXA-17, blaOXA-46, blaOXA-74, blaOXA-101, blaOXA-142 were also described. Other resistance mechanisms, like aac(6)-Ib and aacA29a were the most common determinants of aminoglycoside resistance and amino acid substitutions in gyrA, parC, and parE were also confirmed in cases of fluoroquinolone resistant ST111 P. aeruginosa [12,64,66].

4. ST175

This epidemic high-risk clone was first identified in 2005 in the United Kingdom and Canada. Since then, it was reported in Hungary, the Czech Republic, Poland, the United States, China, Spain, and France [69,78]. (Figure 1) In case of ST175, P. aeruginosa infections the predominantly detected resistance mechanisms are associated to specific mutations in chromosomally encoded versatile resistome including oprD for inhibition of carbapenems, ampR for AmpC overexpression, mexZ efflux pumps, gyrA and parC as fluoroquinolone resistance markers [7,70,79]. Furthermore, presence of blaCARB-12, catB7, blaIMP-1, aacA4′-3 in Japan [50], just as blaVIM-2, blaIMP-22, aac(6)-Ib in Spain were also confirmed associated to class I integron [78]. In a study conducted in Spain, a VIM-47 producing P. aerugonosa ST175 strain was reported [59].
In 2019, an MDR P. aeruginosa ST175 was identified in Spain. It carried blaVIM-20 and blaOXA-681 in class I integron on a plasmid. OXA-681 is a variant of OXA-2, and specific amino acid differences at position 159 and 160 distinguish the two beta-lactamases. OXA-681 is able to hydrolyze cephalosporins, including ceftolozane and induces cross-resistance to ceftolozane-tazobactam and ceftazidime-avibactam. Thereby it may cause serious clinical problems, because new combinations with antipseudomonal effect like ceftolozane-tazobactam and ceftazidime-avibactam are the most effective and recommended options for therapy of MDR P. aeruginosa infections. On the other hand, blaOXA-681 is located on a plasmid in a class I integron thus, it enables this resistance determinant for further dissemination. Gene accession numbers are available: ST175 genome sequence SRX5389644, blaOXA-681 MH986647.1 [69] (Table 1).
Recently, an interregional dissemination of ST175 MDR P. aeruginosa in Spain has been reported. Of the collected 33 strains, the majority carried blaVIM-2 however, blaVIM-1, blaIMP-8, blaVIM-20, blaOXA-2, blaOXA-101, blaOXA-210 were also detected. The coexisting resistance genes showed a wide variety, including aac(6)-Ib, aac(6)-Ib-cr, together with aadA13, aadA1, blaTEM-1A, blaAER1, sul, qnrVC1, and catB7 [80].

5. ST233

Initially, ST233 was reported as a high-risk clone in Mexico, in the United States, in Japan, and in South Africa [81,82,83] (Figure 1). Earlier, this clone was described as colistin susceptible but in case of an extensively drug-resistant (XDR) strain resistance to colistin in 2013 was reported [81]. The first whole genome sequence of this clone was reported in Germany. The detected resistance genes sul1, tet(G), blaVIM-2, blaOXA-4, blaOXA-50, blaPAO, aac(3)-Id, aadA2, aph(3′)-IIb, dfrB5, fosA, catB7 were all located on bacterial chromosome. Assigned accession numbers CP017293 and CP017294 are added to GenBank (Table 1). In this study, the ST233 strains was exposed to colistin and colistin resistant strains were successfully selected through developing mutations in active genes contributing in lipopolysaccharide synthesis [71].
Whole genome sequencing was also performed on an XDR strain of ST233, called K34-7 in Norway. Its genome was built up by a chromosome and a small plasmid. The XDR K34-7 phenotype was encoded by resistance genes found in three class I integrons in chromosome, including aac(3), aac(3)-I, aac(6′)-Il, aadA2 and aph(3′)-IIb, blaOXA-4, blaOXA-486, blaPDC-3 and blaVIM-2, catB, cmlA6, and floR, dfrB5, fosA, tetG and as an accessoric feature, TetK tetracycline efflux pump was encoded on plasmid. This complete genome is available at GenBank under the accession numbers CP029707 and CP029708 [72].
Further studies demonstrated the presence of blaIMP-1 in Singapore [84], the copresence of blaVIM-2, blaOXA-4 with chromosomal mutations in gyrA and parC in Germany, France, Romania, US, and India [12]. Along with ST235 and ST111, blaNDM-1 was also detected in ST233 in tertiary care hospitals in Egypt in 2015 [85].
An interesting aspect of this clone is the confirmed case of reverse zoonotic effect in Brazil, called as zoo anthroponotic transmission. A dog was suffering from severe ear infection and by laboratory tests carbapenem-resistant ST233 P. aeruginosa was identified from this infected ear, oral, and rectal swab and later from the pet owner’s feces and also on the household settings. Interestingly, the pet owner, a 50-year-old man had 1-month long hospital stay in the ICU and after the successful recovery he was released from the hospital a month before the onset of the dog’s symptoms. This strain of ST233 carried chromosomally encoded beta-lactamases, namely blaVIM-2, blaPAO, blaOXA-4, blaOXA-50, and other different resistance determinants such as aadA2, aac(3)-Id, aph(3)-IIb), sul-1, tet(G), fosA, catB7, and cmlA1. These findings made attention for the colonization possibility in the household environments and further transmission to pets of hospital-acquired human pathogens, such as MDR P. aeruginosa [86].

6. ST277

Strains of ST277 are detected predominantly in Brazil from various clinical specimens. These strains have a quite characteristic resistance pattern that is remarkably restricted to the Brazilian area. These resistance markers comprise blaSPM-1, blaOXA-56, blaPAO, rmtD, aacA4, aac(6)-Ib, aac(6)-Ib-cr, aph(3′)-IIb, and aadA7. In certain cases, OXA-variants, like blaOXA-396 and blaOXA-50, as well as fosA, sul-1, catB7 with chromosomal gyrA and parC mutations were also reported in strains of ST277. The related whole genome sequences are available under MVOB00000000 and JPSS00000000 accession numbers at GenBank [12,27,87] (Table 1).
Interestingly, scarce reports detail ST277 out of Brazil however, in the UK and Japan, ST277 has been already described. In Japan, this clone was identified with quite different genomic properties, it carried blaIMP-1, blaIMP-10, aacA1 genes in urine samples [50]. In 2016, a SPM-1 producing P. aeruginosa ST277 that was only susceptible to colistin was reported in the UK from a patient who was hospitalized earlier in Brazil [88].
According to a study, which performed a phylogenetic analysis of almost fifty ST277 strains, the Brazilian isolates have a big number of single nucleotide polymorphisms and distinctively bear genomic islands (In163 and PAGI-25) compared to other ST277 genomes described in Asia, Europe, or North America. The presence of these special elements could explain the widespread dissemination of this endemic clone in Brazil [89].
Additionally, P. aeruginosa ST277 carried a 763,863 bp chromosomally coded unique region comprising two new genomic islands (PAGI-13 and PAGI-14), a mobile element, an integrative and conjugative element (ICE) associated to blaSPM-1. Furthermore, rmtD and In163 are inserted in PAGI-13 while PAGI-14 has genes encoding proteins related to type III restriction system and phages [87].
Strains of ST277 were isolated from microbiota of migratory birds in Brazil, suggesting that these birds might have played an important role in the widespread dissemination in this territory [38,90]. In this geographical region, the most commonly detected carbapenem resistance mechanism is blaSPM-1 (São Paulo metallo-β-lactamase) in clinical samples of MDR P. aeruginosa. Migratory bird-associated ST277 strains carried also blaSPM, and these strains were susceptible only to colistin and contained aac(6′)-Ib-cr, rmtD1, aacA4 [90]. Furthermore, P. aeruginosa ST277 strains were also recovered from environmental water samples in Brazil [91].

7. ST357, ST654 and ST773

ST357 is also listed among high-riks clones and it is characterized by different blaIMP determinants namely, blaIMP-1, blaIMP-6, blaIMP-7, blaIMP-10, blaIMP-11 [12,50,92,93]. Other beta-lactamases were described in ST357 as blaOXA-2, blaOXA-4, and blaOXA-10 [12,94], blaVEB-1-like [12], blaPER-1 [52], blaGES-5, and blaVIM-2 [92]. Fosfomycin resistance encoding fos1, fosE, and a variety of aminoglycoside resistance genes such as aadA11, A2, B, aacA3, and 4, aph(3)-VIa, aac(6)-Ib, aph(6)-Id were also described [12,52,92,93,94].
ST654 was also reported as a blaIMP carrier, and blaIMP-1 and blaIMP-26 were reported from Singapore [84]. In Sweden, blaVIM-2 positive ST654 was reported in a patient who was hospitalized earlier in Tunisia [47]. Recently, VIM-producing P. aeruginosa ST654 strains were reported from a tertiary and quaternary hospital in Saudi Arabia [95]. ST654 was reported as blaKPC-2 positive in Argentina [96]. Furthermore, blaNDM-1 carriage was also reported in the UK [19].
In the case of ST773 blaVIM-2 and blaOXA-10 in India [53], the carriage of blaVEB-1 associated to aac(3)-Ia, aadA1, aadB in Vietnam [52], blaOXA-181 in the UK [19], blaVIM-4 and blaIMP-2 in Iran were reported [97].
However, recently, blaNDM-1 was also confirmed in ST773. This strain developed resistance to tobramycin, ciprofloxacin, and levofloxacin, and showed susceptibility to colistin. This strain of ST773 carried qnrVC1 fluoroquinolone resistance marker localized on class I integron that was originated from Vibrio cholerae. Besides this resistance marker, that ST773 strain carried several other genes, such as blaOXA-50-like, blaPAO, rmtB, aph(3′)-Iib, tetG, fosA, catB7, and sul1. Whole genome sequence of this strain was deposited in GenBank under the accession number RHDU00000000 [20]. A blaNDM-1 positive ST773 strain was also reported in USA from a patient who received medical care earlier in India due to her intraabdominal surgery. Whole genome sequence data are deposited at BioSample: SAMN12307670 [74] (Table 1).

8. Discussion

Emergence and dissemination of P. aeruginosa international high-risk clones are great challenge worldwide [54,81,98]. MDR and XDR strains of high-risk P. aeruginosa are frequently identified in nosocomial infections and these cause difficult to treat infections as limited treatment options are available [60]. Furthermore, genome of P. aeurginosa has its complexitiy and high variability, therefore various resistance genes can be acquired from non-fermentative bacteria or even from different strains of Enterobacterales [74].
Development of MDR strain depends on given geographic area’s features, namely trends of antibiotic consumptions, patterns of transmittable resistant determinants among nosocomial pathogens, travelling habits, previous hospitalization events [11,47,60,87]. In addition, in several countries, such as Portugal, Spain, Romania, Italy, Croatia, Sweden, Norway, UK, US, India, Korea, and Japan, many clones (e.g., ST235) circulate with quite similar resistance pattern [12].
The most commonly detected P. aeruginosa clone is ST235 with a wide variety of beta-lactamases, including the most frequent blaVIM-2, blaOXA-2, blaKPC-2, blaPAO, and blaNDM-1. Moreover, blaFIM-1 was also reported in ST235 in Italy, however, this is the only detection of blaFIM so far [42]. A few years ago, blaNDM-1 was the dominant MBL described in ST235, [11,52,60,61] but it has disseminated with an increasing tendency, since it was also detected in ST111 [68], ST233 [85], ST654 [19], and ST773 [20,74] (Table 2). Beside the most frequently isolated ST235, other sequence types have also important features. In ST175, OXA-681 was reported, which hydrolyzes ceftolozane and induces cross-resistance to ceftolozane-tazobactam and ceftazidime-avibactam. Possible transfer of blaOXA-681 contributes to diverse resistance pattern of P. aeruginsa and adds to the disquieting challenges related to antibiotic resistance [69].
ST235 and ST111 strains show mainly positivity for different ESBL production (blaPES-1, blaBEL-1, blaGES, blaPER), these genes are associated to blaOXA variants and in certain cases to distinctive types of blaVIM or blaIMP. Further resistance mechanisms against aminoglycosides, fluoroquinolones (mainly mutations in gyrA and parC), fosfomycin, tetracycline, and sulfonamides were also detected [12]. Recently, a study conducted in Greece reported predominance of VIM producing ST111 amd ST235. Interstingly, blaVIM genes were incorporated into three integron types, namely, In59, In595, and In1760 [99].
The analyzed high-risk clones are worldwide disseminated, but as an exception, the ST277 is detected mostly in Brazil and shows a relevant spreading tendency in that geographical area [27,87]. Strains of ST277 carry distinct resistomes that are linked to blaSPM-1 and interestingly these strains are particularly colistin-sensitive. According to a study, Brazilian ST277 strains have several single nucleotid polymorphisms, and carry distinct genomic islands, phages, and CRISPR-Cas system compared to other ST277 genomes described in other countries, and these features could be the explanation for epidemic spread of ST277 in Brazil [27,87,89,100]. In strains of ST277, specific PAGIs were reported, that belong to ICEs. It must be underlined that ICEs play an important role in mobilization of carbapenemase genes [101]. It also turned out that migratory birds might have played an important role in transmission of ST277 in Brazil, furthermore, in environmental water sources, ST277 could be also isolated [90,91]. Additionally, other studies supported the zoonotic impact of MDR P. aeruginosa ST233, that these high-risk clones are able to be transmitted from human individuals to pets and the bacteria can circulate between them [86].
These features all underline the importance of possible exchange of resistance determinants and clones between animals, humans, environmental, and hospital source. Therefore, the “One health” approach seems the most accurate one to cope with antibiotic resistance.
As a summary: new antimicrobial agents and protocols for therapy are urgently needed to combat infections caused by MDR P. aeruginosa. Early detection and analysis by whole genome sequencing can help to follow evolutionary changes in MDR P. aeruginosa, to track dissemination of novel resistance determinants and emergence of international high-risk clones.

Author Contributions

B.K. writing—original draft preparation; D.G. writing—review and editing, D.S.—supervision. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding. The APC was covered by B.K.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bassetti, M.; Vena, A.; Croxatto, A.; Righi, E.; Guery, B. How to manage Pseudomonas aeruginosa infections. Drugs Context 2018, 7, 212527. [Google Scholar] [CrossRef] [PubMed]
  2. Burrows, L.L. The therapeutic pipeline for Pseudomonas aeruginosa infections. ACS Infect. Dis. 2018, 4, 1041–1047. [Google Scholar] [CrossRef]
  3. Römling, U.; Balsalobre, C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J. Intern Med. 2012, 272, 541–561. [Google Scholar] [CrossRef]
  4. Rodriguez-Rojas, A.; Oliver, A.; Blazquez, J. Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. J. Infect. Dis. 2012, 205, 121–127. [Google Scholar] [CrossRef]
  5. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Livermore, D.M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 2009, 64 (Suppl. 1), i29–i36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Botelho, J.; Grosso, F.; Peixe, L. Antibiotic resistance in Pseudomonas aeruginosa—Mechanisms, epidemiology and evolution. Drug Resist Updat. 2019, 44, 26–47. [Google Scholar] [CrossRef]
  8. Oliver, A.; Mulet, X.; López-Causapé, C.; Juan, C. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat. 2015, 21–22, 41–59. [Google Scholar] [CrossRef] [PubMed]
  9. Juhász, E.; Iván, M.; Pongrácz, J.; Kristóf, K. Uncommon non-fermenting Gram-negative rods as pathogens of lower respiratory tract infection. Orv. Hetil. 2018, 159, 23–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [Google Scholar] [CrossRef]
  11. Carattoli, A.; Fortini, D.; Galetti, R.; Garcia-Fernandez, A.; Nardi, G.; Orazi, D.; Capone, A.; Majolino, I.; Proia, A.; Mariani, B.; et al. Isolation of NDM-1-producing Pseudomonas aeruginosa sequence type ST235 from a stem cell transplant patient in Italy, May 2013. Euro. Surveill. 2013, 18, 20633. [Google Scholar] [CrossRef] [PubMed]
  12. Kos, V.N.; Déraspe, M.; McLaughlin, R.E.; Whiteaker, J.D.; Roy, P.H.; Alm, R.A.; Corbeil, J.; Gardner, H. The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility. Antimicrob. Agents Chemother. 2015, 59, 427–436. [Google Scholar] [CrossRef] [Green Version]
  13. Breidenstein, E.B.M.; de la Fuente-Núñez, C.; Hancock, R.E.W. Pseudomonas aeruginosa: All roads lead to resistance. Trends Microbiol. 2011, 19, 419–426. [Google Scholar] [CrossRef]
  14. Chevalier, S.; Bouffartigues, E.; Bodilis, J.; Maillot, O.; Lesouhaitier, O.; Feuilloley, M.G.; Orange, N.; Dufour, A.; Cornelis, P. Structure, function and regulation of Pseudomonas aeruginosa porins. FEMS Microbiol. Rev. 2017, 41, 698–722. [Google Scholar] [CrossRef]
  15. Hancock, R.E.; Speert, D.P. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and impact on treatment. Drug Resist. Updat. 2000, 3, 247–255. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Livermore, D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin. Infect. Dis. 2002, 34, 634–640. [Google Scholar] [CrossRef] [Green Version]
  17. Laudy, A.E.; Róg, P.; Smolińska-Król, K.; Ćmiel, M.; Słoczyńska, A.; Patzer, J.; Dzierżanowska, D.; Wolinowska, R.; Starościak, B.; Tyski, S. Prevalence of ESBL-producing Pseudomonas aeruginosa isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods. PLoS ONE 2017, 12, e0180121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Queenan, A.M.; Bush, K. Carbapenemases: The versatile beta-lactamases. Clin. Microbiol. Rev. 2007, 20, 440–458. [Google Scholar] [CrossRef] [Green Version]
  19. Wright, L.L.; Turton, J.F.; Livermore, D.M.; Hopkins, K.L.; Woodford, N. Dominance of international ‘high-risk clones’ among metallo-beta-lactamase-producing Pseudomonas aeruginosa in the UK. J. Antimicrob. Chemother. 2015, 70, 103–110. [Google Scholar] [CrossRef]
  20. Kocsis, B.; Toth, A.; Gulyas, D.; Ligeti, B.; Katona, K.; Rokusz, L.; Szabo, D. Acquired qnrVC1 and blaNDM-1 resistance markers in an international high-risk Pseudomonas aeruginosa ST773 clone. J. Med. Microbiol. 2019, 68, 336–338. [Google Scholar] [CrossRef]
  21. Gaballah, A.; Elbaradei, A.; Elsheredy, A.; Kader, O. Emergence of blaVEB and blaGES among VIM-producing Pseudomonas aeruginosa clinical isolates in Alexandria, Egypt. Acta Microbiol. Immunol. Hung. 2019, 66, 131–142. [Google Scholar] [CrossRef] [Green Version]
  22. Del Barrio-Tofiño, E.; López-Causapé, C.; Oliver, A. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired beta-lactamases: 2020 update. Int. J. Antimicrob. Agents 2020, 56, 106196. [Google Scholar] [CrossRef]
  23. Khalili, Y.; Yekani, M.; Goli, H.R.; Memar, M.Y. Characterization of carbapenem-resistant but cephalosporin-susceptible Pseudomonas aeruginosa. Acta Microbiol. Immunol. Hung. 2019, 66, 529–540. [Google Scholar] [CrossRef] [PubMed]
  24. Gajdács, M. Carbapenem-Resistant but Cephalosporin-Susceptible Pseudomonas aeruginosa in Urinary Tract Infections: Opportunity for Colistin Sparing. Antibiotics 2020, 9, 53. [Google Scholar] [CrossRef] [Green Version]
  25. Poole, K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2005, 49, 479–487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Wachino, J.; Arakawa, Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram negative bacteria: An update. Drug Resist. Updat. 2012, 15, 133–148. [Google Scholar] [CrossRef] [PubMed]
  27. Galetti, R.; Andrade, L.N.; Varani, A.M.; Darinia, A.L.C. SPM-1-producing Pseudomonas aeruginosa ST277 carries chromosomal pack of acquired resistance genes: An example of high-risk clone associated to “intrinsic resistome”. J. Glob. Antimicrob. Resist. 2019, 16, 183–186. [Google Scholar] [CrossRef]
  28. Lee, J.Y.; Park, Y.K.; Chung, E.S.; Na, I.Y.; Ko, K.S. Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa. Sci. Rep. 2016, 6, 25543. [Google Scholar] [CrossRef]
  29. Romano, K.P.; Warrier, T.; Poulsen, B.E.; Nguyen, P.H.; Loftis, A.R.; Saebi, A.; Pentelute, B.L.; Hung, D.T. Mutations in pmrB Confer Cross-Resistance between the LptD Inhibitor POL7080 and Colistin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2019, 63, e00511-19. [Google Scholar] [CrossRef] [Green Version]
  30. Wi, Y.M.; Choi, J.Y.; Lee, J.Y.; Kang, C.I.; Chung, D.R.; Peck, K.R.; Song, J.H.; Ko, K.S. Emergence of colistin resistance in Pseudomonas aeruginosa ST235 clone in South Korea. Int. J. Antimicrob. Agents 2017, 49, 767–769. [Google Scholar] [CrossRef] [PubMed]
  31. Tahmasebi, H.; Dehbashi, S.; Arabestani, M.R. Co-harboring of mcr-1 and β-lactamase genes in Pseudomonas aeruginosa by high-resolution melting curve analysis (HRMA): Molecular typing of superbug strains in bloodstream infections (BSI). Infect. Genet. Evol. 2020, 85, 104518. [Google Scholar] [CrossRef] [PubMed]
  32. Chen, F.J.; Lo, H.J. Molecular mechanisms of fluoroquinolone resistance. J. Microbiol. Immunol. Infect. 2003, 36, 1–9. [Google Scholar]
  33. Libisch, B.; Poirel, L.; Lepsanovic, Z.; Mirovic, V.; Balogh, B.; Pászti, J.; Hunyadi, Z.; Dobák, A.; Füzi, M.; Nordmann, P. Identification of PER-1 extended-spectrum beta-lactamase producing Pseudomonas aeruginosa clinical isolates of the international clonal complex CC11 from Hungary and Serbia. FEMS Immunol. Med. Microbiol. 2008, 54, 330–338. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Botelho, J.; Grosso, F.; Peixe, L. ICEs are main reservoirs of ciprofloxacin modifying crpP gene in Pseudomonas aeruginosa. Genes 2020, 11, 889. [Google Scholar] [CrossRef]
  35. Curran, B.; Jonas, D.; Grundmann, H.; Pitt, T.; Dowson, C.G. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J. Clin. Microbiol. 2004, 42, 5644–5649. [Google Scholar] [CrossRef] [Green Version]
  36. De Sales, R.O.; Migliorini, L.B.; Puga, R.; Kocsis, B.; Severino, P. A Core Genome Multilocus Sequence Typing Scheme for Pseudomonas aeruginosa. Front. Microbiol. 2020, 11, 1049. [Google Scholar] [CrossRef] [PubMed]
  37. Woodford, N.; Turton, J.F.; Livermore, D.M. Multiresistant Gram-negative bacteria: The role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol. Rev. 2011, 35, 736–755. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Silva, F.M.; Carmo, M.S.; Silbert, S.; Gales, A.C. SPM-1-producing Pseudomonas aeruginosa: Analysis of the ancestor relationship using multilocus sequence typing, pulsed-field gel electrophoresis, and automated ribotyping. Microb. Drug Resist. 2011, 17, 215–220. [Google Scholar] [CrossRef]
  39. Miyoshi-Akiyama, T.; Tada, T.; Ohmagari, N.; Viet Hung, N.; Tharavichitkul, P.; Pokhrel, B.M.; Gniadkowski, M.; Shimojima, M.; Kirikae, T. Emergence and Spread of Epidemic Multidrug-Resistant Pseudomonas aeruginosa. Genome Biol. Evol. 2017, 9, 3238–3245. [Google Scholar] [CrossRef]
  40. Bogaerts, P.; Bauraing, C.; Deplano, A.; Glupczynski, Y. Emergence and dissemination of BEL-1-producing Pseudomonas aeruginosa in Belgium. Antimicrob. Agents Chemother. 2007, 51, 1584–1585. [Google Scholar] [CrossRef] [Green Version]
  41. Botelho, J.; Grosso, F.; Sousa, C.; Peixe, L. Characterization of a new genetic environment associated with GES-6 carbapenemase from a Pseudomonas aeruginosa isolate belonging to the high-risk clone ST235. J. Antimicrob. Chemother. 2015, 70, 615–617. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Pollini, S.; Maradei, S.; Pecile, P.; Olivo, G.; Luzzaro, F.; Docquier, J.D.; Rossolini, G.M. FIM-1, a new acquired metallo-beta-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy. Antimicrob. Agents Chemother. 2013, 57, 410–416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Viedma, E.; Juan, C.; Acosta, J.; Zamorano, L.; Otero, J.R.; Sanz, F.; Chaves, F.; Oliver, A. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother. 2009, 53, 4930–4933. [Google Scholar] [CrossRef] [Green Version]
  44. Juan, C.; Zamorano, L.; Mena, A.; Albertí, S.; Pérez, J.L.; Oliver, A. Metallo-beta-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. J. Antimicrob. Chemother. 2010, 65, 474–478. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Larché, J.; Pouillot, F.; Essoh, C.; Libisch, B.; Straut, M.; Lee, J.C.; Soler, C.; Lamarca, R.; Gleize, E.; Gabard, J.; et al. Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages. Antimicrob. Agents Chemother. 2012, 56, 6175–6180. [Google Scholar] [CrossRef] [Green Version]
  46. Pfennigwerth, N.; Geis, G.; Gatermann, S.G.; Kaase, M. Description of IMP-31, a novel metallo-beta-lactamase found in an ST235 Pseudomonas aeruginosa strain in Western Germany. J. Antimicrob. Chemother. 2015, 70, 1973–1980. [Google Scholar]
  47. Samuelsen, Ø.; Toleman, M.A.; Sundsfjord, A.; Rydberg, J.; Leegaard, T.M.; Walder, M.; Lia, A.; Ranheim, T.E.; Rajendra, Y.; Hermansen, N.O.; et al. Molecular Epidemiology of Metallo-beta -Lactamase-Producing Pseudomonas aeruginosa Isolates from Norway and Sweden Shows Import of International Clones and Local Clonal Expansion. Antimicrob. Agents Chemother. 2010, 54, 346–352. [Google Scholar] [CrossRef] [Green Version]
  48. Seok, Y.; Bae, I.K.; Jeong, S.H.; Kim, S.H.; Lee, H.; Lee, K. Dissemination of IMP-6 metallo-beta-lactamase-producing Pseudomonas aeruginosa sequence type 235 in Korea. J. Antimicrob. Chemother. 2011, 66, 2791–2796. [Google Scholar] [CrossRef]
  49. Hong, J.S.; Yoon, E.J.; Lee, H.; Jeong, S.H.; Lee, K. Clonal dissemination of Pseudomonas aeruginosa sequence type 235 isolates carrying blaIMP-6 and emergence of blaGES-24 and blaIMP-10 on novel genomic islands PAGI-15 and PAGI-16 in South Korea. Antimicrob. Agents Chemother. 2016, 60, 7216–7223. [Google Scholar] [PubMed] [Green Version]
  50. Mano, Y.; Saga, T.; Ishii, Y.; Yoshizumi, A.; Bonomo, R.A.; Yamaguchi, K.; Tateda, K. Molecular analysis of the integrons of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan. BMC Microbiol. 2015, 21, 41. [Google Scholar]
  51. Treepong, P.; Kos, V.N.; Guyeux, C.; Blanc, D.S.; Bertrand, X.; Valot, B.; Hocquet, D. Global emergence of the widespread Pseudomonas aeruginosa ST235 clone. Clin. Microbiol. Infect. 2018, 24, 258. [Google Scholar] [CrossRef] [Green Version]
  52. Tada, T.; Nhung, P.H.; Miyoshi-Akiyama, T.; Shimada, K.; Tsuchiya, M.; Phuong, D.M.; Anh, N.Q.; Ohmagari, N.; Kirikae, T. Multidrug-Resistant Sequence Type 235 Pseudomonas aeruginosa Clinical Isolates Producing IMP-26 with Increased Carbapenem-Hydrolyzing Activities in Vietnam. Antimicrob. Agents Chemother. 2016, 60, 6853–6858. [Google Scholar] [CrossRef] [Green Version]
  53. Kim, M.J.; Bae, I.K.; Jeong, S.H.; Kim, S.H.; Song, J.H.; Choi, J.Y.; Yoon, S.S.; Thamlikitkul, V.; Hsueh, P.R.; Yasin, R.M.; et al. Dissemination of metallo-beta-lactamase-producing Pseudomonas aeruginosa of sequence type 235 in Asian countries. J. Antimicrob. Chemother. 2013, 68, 2820–2824. [Google Scholar] [CrossRef] [Green Version]
  54. Edelstein, M.V.; Skleenova, E.N.; Shevchenko, O.V.; D’souza, J.W.; Tapalski, D.V.; Azizov, I.S.; Sukhorukova, M.V.; Pavlukov, R.A.; Kozlov, R.S.; Toleman, M.A.; et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: A longitudinal epidemiological and clinical study. Lancet Infect. Dis. 2013, 13, 867–876. [Google Scholar] [CrossRef]
  55. Abril, D.; Marquez-Ortiz, R.A.; Castro-Cardozo, B.; Moncayo-Ortiz, J.I.; Olarte Escobar, N.M.; Corredor Rozo, Z.L.; Reyes, N.; Tovar, C.; Sánchez, H.F.; Castellanos, J.; et al. Genome plasticity favours double chromosomal Tn4401b-blaKPC-2 transposon insertion in the Pseudomonas aeruginosa ST235 clone. BMC Microbiol. 2019, 19, 45. [Google Scholar] [CrossRef]
  56. Vanegas, J.M.; Cienfuegos, A.V.; Ocampo, A.M.; López, L.; del Corral, H.; Roncancio, G.; Sierra, P.; Echeverri-Toro, L.; Ospina, S.; Maldonado, N.; et al. Similar frequencies of Pseudomonas aeruginosa isolates producing KPC and VIM carbapenemases in diverse genetic clones at tertiary-care hospitals in Medellin, Colombia. J. Clin. Microbiol. 2014, 52, 3978–3986. [Google Scholar] [CrossRef] [Green Version]
  57. De Paula-Petroli, S.B.; Campana, E.H.; Bocchi, M.; Bordinhão, T.; Picão, R.C.; Yamada-Ogatta, S.F.; Carrara-Marroni, F.E. Early detection of a hypervirulent KPC-2-producing Pseudomonas aeruginosa ST235 in Brazil. J. Glob. Antimicrob. Resist. 2018, 12, 153–154. [Google Scholar] [CrossRef] [PubMed]
  58. Juan, C.; Beceiro, A.; Gutiérrez, O.; Albertí, S.; Garau, M.; Pérez, J.L.; Bou, G.; Oliver, A. Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. Antimicrob. Agents Chemother. 2008, 52, 3589–3596. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Zamorano, L.; Mulet, X.; Garau, M.; Gallegos, C.; Juan, C.; Pérez, J.L.; Oliver, A. VIM-47, a New Variant of the Autochthonous Metallo-beta-Lactamase VIM-13 from the Balearic Islands in Spain. Antimicrob. Agents Chemother. 2016, 60, 3251–3252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Janvier, F.; Jeannot, K.; Tessé, S.; Robert-Nicoud, M.; Delacour, H.; Rapp, C.; Mérens, A. Molecular characterization of blaNDM-1 in a sequence type 235 Pseudomonas aeruginosa isolate from France. Antimicrob. Agents Chemother. 2013, 57, 3408–3411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Loconsole, D.; Accogli, M.; Monaco, M.; Del Grosso, M.; De Robertis, A.L.; Morea, A.; Capozzi, L.; Del Sambro, L.; Simone, A.; De Letteriis, V.; et al. First detection of autochthonous extensively drug-resistant NDM-1 Pseudomonas aeruginosa ST235 from a patient with bloodstream infection in Italy, October 2019. Antimicrob. Resist. Infect. Control. 2020, 9, 73. [Google Scholar] [CrossRef] [PubMed]
  62. Recio, R.; Villa, J.; Viedma, E.; Orellana, M.Á.; Lora-Tamayo, J.; Chaves, F. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm. Int. J. Antimicrob. Agents. 2018, 52, 172–179. [Google Scholar] [CrossRef]
  63. Witney, A.A.; Gould, K.A.; Pope, C.F.; Bolt, F.; Stoker, N.G.; Cubbon, M.D.; Bradley, C.R.; Fraise, A.; Breathnach, A.S.; Butcher, P.D.; et al. Genome sequencing and characterization of an extensively drug-resistant sequence type 111 serotype O12 hospital outbreak strain of Pseudomonas aeruginosa. Clin. Microbiol. Infect. 2014, 20, O609–O618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Guzvinec, M.; Izdebski, R.; Butic, I.; Jelic, M.; Abram, M.; Koscak, I.; Baraniak, A.; Hryniewicz, W.; Gniadkowski, M.; Andrasevic, A.T. Sequence types 235, 111, and 132 predominate among multidrug-resistant Pseudomonas aeruginosa clinical isolates in Croatia. Antimicrob. Agents Chemother. 2014, 58, 6277–6283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Papagiannitsis, C.C.; Studentova, V.; Ruzicka, F.; Tejkalova, R.; Hrabak, J. Molecular characterization of metallo-b-lactamase-producing Pseudomonas aeruginosa in a Czech hospital (2009–2011). J. Med. Microbiol. 2013, 62, 945–947. [Google Scholar] [CrossRef] [Green Version]
  66. Vatcheva-Dobrevska, R.; Mulet, X.; Ivanov, I.; Zamorano, L.; Dobreva, E.; Velinov, T.; Kantardjiev, T.; Oliver, A. Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals. Microb. Drug Resist. 2013, 19, 355–361. [Google Scholar] [CrossRef]
  67. Van der Bij, A.K.; Van der Zwan, D.; Peirano, G.; Severin, J.A.; Pitout, J.D.; Van Westreenen, M.; Goessens, W.H. Metallo-beta-lactamase producing Pseudomonas aeruginosa in the Netherlands: The nationwide emergence of a single sequence type. Clin. Microbiol. Infect. 2012, 18, E369–E372. [Google Scholar] [CrossRef] [Green Version]
  68. Turton, J.F.; Wright, L.; Underwood, A.; Witney, A.A.; Chan, Y.T.; Al-Shahib, A.; Arnold, C.; Doumith, M.; Patel, B.; Planche, T.D.; et al. High-Resolution Analysis by Whole-Genome Sequencing of an International Lineage (Sequence Type 111) of Pseudomonas aeruginosa Associated with Metallo-Carbapenemases in the United Kingdom. J. Clin. Microbiol. 2015, 53, 2622–2631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  69. Arca-Suárez, J.; Fraile-Ribot, P.; Vázquez-Ucha, J.C.; Cabot, G.; Martínez-Guitián, M.; Lence, E.; González-Bello, C.; Beceiro, A.; Rodríguez-Iglesias, M.; Galán-Sánchez, F.; et al. Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone. Antimicrob. Agents Chemother. 2019, 63, e01110-19. [Google Scholar] [CrossRef] [Green Version]
  70. Cabot, G.; López-Causapé, C.; Ocampo-Sosa, A.A.; Sommer, L.M.; Domínguez, M.A.; Zamorano, L.; Juan, C.; Tubau, F.; Rodríguez, C.; Moyà, B.; et al. Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrob. Agents Chemother. 2016, 60, 7415–7423. [Google Scholar]
  71. Dößelmann, B.; Willmann, M.; Steglich, M.; Bunk, B.; Nübel, U.; Peter, S.; Neher, R.A. Rapid and Consistent Evolution of Colistin Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa during Morbidostat Culture. Antimicrob. Agents Chemother. 2017, 61, e00043-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Taiaroa, G.; Samuelsen, Ø.; Kristensen, T.; Økstad, O.A.L.; Heikal, A. Complete Genome Sequence of Pseudomonas aeruginosa K34-7, a Carbapenem-Resistant Isolate of the High-Risk Sequence Type 233. Microbiol. Resour. Announc. 2018, 7, e00886-18. [Google Scholar] [CrossRef] [Green Version]
  73. Silveira, M.; Albano, R.; Asensi, M.; Assef, A.P. The draft genome sequence of multidrug-resistant Pseudomonas aeruginosa strain CCBH4851, a nosocomial isolate belonging to clone SP (ST277) that is prevalent in Brazil. Mem. Inst. Oswaldo. Cruz. 2014, 109, 1086–1087. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Khan, A.; Shropshire, W.C.; Hanson, B.; Dinh, A.Q.; Wanger, A.; Ostrosky-Zeichner, L.; Arias, C.A.; Miller, W.R. Simultaneous Infection with Enterobacteriaceae and Pseudomonas aeruginosa Harboring Multiple Carbapenemases in a Returning Traveler Colonized with Candida auris. Antimicrob. Agents Chemother. 2020, 64, e01466-19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Correa, A.; Montealegre, M.C.; Mojica, M.F.; Maya, J.J.; Rojas, L.J.; De La Cadena, E.P.; Ruiz, S.J.; Recalde, M.; Rosso, F.; Quinn, J.P.; et al. First report of a Pseudomonas aeruginosa isolate coharboring KPC and VIM carbapenemases. Antimicrob. Agents Chemother. 2012, 56, 5422–5423. [Google Scholar] [CrossRef] [Green Version]
  76. Castanheira, M.; Toleman, M.A.; Jones, R.N.; Schmidt, F.J.; Walsh, T.R. Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrob. Agents Chemother. 2004, 48, 4654–4661. [Google Scholar] [CrossRef] [Green Version]
  77. Wendel, A.F.; Kolbe-Busch, S.; Ressina, S.; Schulze-Röbbecke, R.; Kindgen-Milles, D.; Lorenz, C.; Pfeffer, K.; MacKenzie, C.R. Detection and termination of an extended low-frequency hospital outbreak of GIM-1-producing Pseudomonas aeruginosa ST111 in Germany. Am. J. Infect. Control. 2015, 43, 635–639. [Google Scholar] [CrossRef]
  78. Viedma, E.; Juan, C.; Villa, J.; Barrado, L.; Orellana, M.A.; Sanz, F.; Otero, J.R.; Oliver, A.; Chaves, F. VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain. Emerg. Infect. Dis. 2012, 18, 1235–1241. [Google Scholar] [CrossRef]
  79. López-Causapé, C.; Cabot, G.; Del Barrio-Tofiño, E.; Oliver, A. The Versatile Mutational Resistome of Pseudomonas aeruginosa. Front. Microbiol. 2018, 9, 685. [Google Scholar] [CrossRef]
  80. Perez-Vazquez, M.; Sola-Campoy, P.J.; Zurita, Á.M.; Avila, A.; Gomez-Bertomeu, F.; Solis, S.; Lopez-Urrutia, L.; Gónzalez-Barberá, E.M.; Cercenado, E.; Bautista, V.; et al. Carbapenemase-producing Pseudomonas aeruginosa in Spain: Interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. Int. J. Antimicrob. Agents 2020, 56, 106026. [Google Scholar] [CrossRef]
  81. Aguilar-Rodea, P.; Zúñiga, G.; Rodríguez-Espino, B.A.; Olivares Cervantes, A.L.; Gamiño Arroyo, A.E.; Moreno-Espinosa, S.; de la Rosa Zamboni, D.; López Martínez, B.; Castellanos-Cruz, M.d.C.; Parra-Ortega, I.; et al. Identification of extensive drug resistant Pseudomonas aeruginosa strains: New clone ST1725 and high-risk clone ST233. PLoS ONE 2017, 12, e0172882. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Perez, F.; Hujer, A.M.; Marshall, S.H.; Ray, A.J.; Rather, P.N.; Suwantarat, N.; Dumford, D., 3rd; O’Shea, P.; Domitrovic, T.N.J.; Salata, R.A.; et al. Extensively drug-resistant Pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: A new genetic resistance determinant in Northeast Ohio. Antimicrob. Agents Chemother. 2014, 58, 5929–5935. [Google Scholar] [CrossRef] [Green Version]
  83. Mudau, M.; Jacobson, R.; Minenza, N.; Kuonza, L.; Morris, V.; Engelbrecht, H.; Nicol, M.P.; Bamford, C. Outbreak of multi-drug resistant Pseudomonas aeruginosa bloodstream infection in the haematology unit of a South African Academic Hospital. PLoS ONE 2013, 8, e55985. [Google Scholar] [CrossRef] [Green Version]
  84. Koh, T.H.; Khoo, C.T.; Tan, T.T.; Arshad, M.A.; Ang, L.P.; Lau, L.J.; Hsu, L.Y.; Ooi, E.E. Multilocus sequence types of carbapenem-resistant Pseudomonas aeruginosa in Singapore carrying metallo-beta-lactamase genes, including the novel blaIMP-26 gene. J. Clin. Microbiol. 2010, 48, 2563–2564. [Google Scholar] [CrossRef] [Green Version]
  85. Zafer, M.M.; Al-Agamy, M.H.; El-Mahallawy, H.A.; Amin, M.A.; El Din Ashour, S. Dissemination of VIM-2 producing Pseudomonas aeruginosa ST233 at tertiary care hospitals in Egypt. BMC Infect. Dis. 2015, 15, 122. [Google Scholar] [CrossRef] [Green Version]
  86. Fernandes, M.R.; Sellera, F.P.; Moura, Q.; Carvalho, M.; Rosato, P.N.; Cerdeira, L.; Lincopan, N. Zooanthroponotic Transmission of Drug-Resistant Pseudomonas aeruginosa, Brazil. Emerg. Infect. Dis. 2018, 24, 1160–1162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Silveira, M.C.; Albano, R.M.; Asensi, M.D.; Carvalho-Assef, A.P. Description of genomic islands associated to the multidrug-resistant Pseudomonas aeruginosa clone ST277. Infect. Genet Evol. 2016, 42, 60–65. [Google Scholar] [CrossRef] [PubMed]
  88. Hopkins, K.L.; Meunier, D.; Findlay, J.; Mustafa, N.; Parsons, H.; Pike, R.; Wright, L.; Woodford, N. SPM-1 metallo-beta-lactamase-producing Pseudomonas aeruginosa ST277 in the UK. J. Med. Microbiol. 2016, 65, 696–697. [Google Scholar] [CrossRef]
  89. Silveira, M.C.; Rocha-de-Souza, C.M.; Albano, R.M.; de Oliveira Santos, I.C.; Carvalho-Assef, A.P. Exploring the success of Brazilian endemic clone Pseudomonas aeruginosa ST277 and its association with the CRISPR-Cas system type I-C. BMC Genomics 2020, 21, 255. [Google Scholar] [CrossRef]
  90. Martins, W.M.B.S.; Narciso, A.C.; Cayô, R.; Santos, S.V.; Fehlberg, L.C.C.; Ramos, P.L.; da Cruz, J.B.; Gales, A.C. SPM-1-producing Pseudomonas aeruginosa ST277 clone recovered from microbiota of migratory birds. Diagn Microbiol. Infect. Dis. 2018, 90, 221–227. [Google Scholar] [CrossRef]
  91. Turano, H.; Gomes, F.; Medeiros, M.; Oliveira, S.; Fontes, L.C.; Sato, M.I.; Lincopan, N. Presence of high-risk clones of OXA-23-producing Acinetobacter baumannii (ST79) and SPM-1-producing Pseudomonas aeruginosa (ST277) in environmental water samples in Brazil. Diagn. Microbiol. Infect. Dis. 2016, 86, 80–82. [Google Scholar] [CrossRef] [PubMed]
  92. Papagiannitsis, C.C.; Medvecky, M.; Chudejova, K.; Skalova, A.; Rotova, V.; Spanelova, P.; Jakubu, V.; Zemlickova, H.; Hrabak, J. Molecular Characterization of Carbapenemase-Producing Pseudomonas aeruginosa of Czech Origin and Evidence for Clonal Spread of Extensively Resistant Sequence Type 357 Expressing IMP-7 Metallo-β-Lactamase. Antimicrob. Agents Chemother. 2017, 61, e01811-1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Hrabák, J.; Cervená, D.; Izdebski, R.; Duljasz, W.; Gniadkowski, M.; Fridrichová, M.; Urbásková, P.; Zemlicková, H. Regional spread of Pseudomonas aeruginosa ST357 producing IMP-7 metallo-β-lactamase in Central Europe. J. Clin. Microbiol. 2011, 49, 474–475. [Google Scholar] [CrossRef] [Green Version]
  94. Kainuma, A.; Momiyama, K.; Kimura, T.; Akiyama, K.; Inoue, K.; Naito, Y.; Kinoshita, M.; Shimizu, M.; Kato, H.; Shime, N.; et al. An outbreak of fluoroquinolone-resistant Pseudomonas aeruginosa ST357 harboring the exoU gene. J. Infect. Chemother. 2018, 24, 615–622. [Google Scholar] [CrossRef]
  95. Al-Zahrani, I.A.; Al-Ahmadi, B.M. Dissemination of VIM-producing Pseudomonas aeruginosa associated with high-risk clone ST654 in a tertiary and quaternary hospital in Makkah, Saudi Arabia. J. Chemother. 2021, 33, 12–20. [Google Scholar] [CrossRef]
  96. Pasteran, F.; Faccone, D.; Gomez, S.; De Bunder, S.; Spinelli, F.; Rapoport, M.; Petroni, A.; Galas, M.; Corso, A. Detection of an international multiresistant clone belonging to sequence type 654 involved in the dissemination of KPC-producing Pseudomonas aeruginosa in Argentina. J. Antimicrob. Chemother. 2012, 67, 1291–1293. [Google Scholar] [CrossRef] [Green Version]
  97. Yousefi, S.; Nahaei, M.R.; Farajnia, S.; Aghazadeh, M.; Iversen, A.; Edquist, P.; Maãtallah, M.; Giske, C.G. A multiresistant clone of Pseudomonas aeruginosa sequence type 773 spreading in a burn unit in Orumieh, Iran. APMIS 2013, 121, 146–152. [Google Scholar] [CrossRef]
  98. Chmielarczyk, A.; Pobiega, M.; Ziółkowski, G.; Pomorska-Wesołowska, M.; Romaniszyn, D.; Krawczyk, L.; Wójkowska-Mach, J. Severe infections caused by multidrug-resistant non-fermentative bacilli in southern Poland. Adv. Clin. Exp. Med. 2018, 27, 401–407. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  99. Papagiannitsis, C.C.; Verra, A.; Galani, V.; Xitsas, S.; Bitar, I.; Hrabak, J.; Petinaki, E. Unravelling the Features of Success of VIM-Producing ST111 and ST235 Pseudomonas aeruginosa in a Greek Hospital. Microorganisms 2020, 8, 1884. [Google Scholar] [CrossRef]
  100. Nascimento, A.P.; Ortiz, M.F.; Martins, W.M.; Morais, G.L.; Fehlberg, L.C.; Almeida, L.G.; Ciapina, L.P.; Gales, A.C.; Vasconcelos, A.T. Intraclonal Genome Stability of the Metallo-beta-lactamase SPM-1-producing Pseudomonas aeruginosa ST277, an Endemic Clone Disseminated in Brazilian Hospitals. Front. Microbiol. 2016, 7, 1946. [Google Scholar] [CrossRef] [Green Version]
  101. Botelho, J.; Roberts, A.P.; Leon-Sampedro, R.; Grosso, F.; Peixe, L. Carbapenemases on the move: It’s good to be on ICEs. Mob. DNA 2018, 9, 37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Microorganisms 09 00359 g001 550
Figure 1. Geographic dissemination of the most frequently reported international high risk clones of P. aeruginosa. Figure illustrates reported cases until 2020. (source of map template: http://www.intrafor.com/locations-worldwide-presence.html, accessed on 23 January 2021).
Figure 1. Geographic dissemination of the most frequently reported international high risk clones of P. aeruginosa. Figure illustrates reported cases until 2020. (source of map template: http://www.intrafor.com/locations-worldwide-presence.html, accessed on 23 January 2021).
Microorganisms 09 00359 g001
Table
Table 1. Whole genome sequences of high-risk P. aeruginosa clones from published reports.
Table 1. Whole genome sequences of high-risk P. aeruginosa clones from published reports.
ReferenceCloneAccession Number
Loconsole et al., 2020 [61]ST235JAABOY000000000
Tada et al., 2016 [52]ST235, ST277(SRA): DRA003741
Witney et al., 2014 [63]ST111PRJEB4573
Kos et al., 2015 [15]ST111JUAZ00000000
Turton et al., 2015 [68]ST111ERS716506 to ERS716591
Arca-Suárez et al., 2019 [69] ST175SRX5389644
Cabot et al., 2016 [70]ST175ERS1280254 to ERS1280271 and ERS1280273 to ERS1280276
(European Nucleotide Archive)
Dößelmann et al., 2017 [71]ST233CP017293 and CP017294
Taiaroa et al., 2018 [72]ST233CP029707 CP029708
Silveira et al., 2014 [73]ST277JPSS00000000
Galetti et al., 2019 [27]ST277MVOB00000000
Kos et al., 2015 [15]ST654JTYC00000000
Kocsis et al., 2019 [20]ST773RHDU00000000
Khan et al., 2020 [74]ST773BioSample: SAMN12307670
Table
Table 2. Overview of the most common resistance genes of high-risk P. aeruginosa.
Table 2. Overview of the most common resistance genes of high-risk P. aeruginosa.
The Most Common Clinically Relevant Resistance Genes in P. aeruginosa
CloneBeta-LactamasesAminoglycoside Modifying EnzymesResistance to FluoroquinolonesResistance to ColistinOther
ST235blaPSE-1,
blaBEL-1,
blaPER-1,
blaGES-variants,
blaCTX-M,
blaOXA-2,
blaKPC-2,
blaPAO,
blaIMP-variants,
blaVIM-2 and variants,
blaFIM-1,
blaNDM-1		aacA7,
aph(6)-Id,
aadA1,
aac(6′)-Ib-cr		qnrVC1, mutations in gyrA and parCStrains susceptible to colistin. Sporadic reports of mcr carriage fosA,
cmlA7,
sul-1,
tetA,
tetGcatB7,
ST111blaPSE-1,
blaGES-7,
blaVIM-2,
blaKPC-2,
blaIMP-1 and variants,
blaVEB-1,
blaOXA-2, and variants
blaNDM-1		aac(6)-Ib, aacA29amutations in gyrA, parC, or parEColistin-resistant strain is confirmedmexZ efflux pump, oprD,
sul-1, catB7
ST175blaCARB-12,
blaIMP-1,
blaVIM-2,
blaTEM-1A,
blaAER1,
blaOXA-2 variants,
like
blaOXA-681		aac(6)-1b,
aacA4′-3		qnrVC-1,
mutations in gyrA and parC		No data availableoprD,
ampR,
mexZ efflux pumps,
catB7
ST233blaVIM-2,
blaIMP-1,
blaOXA-4,
blaOXA-50,
blaPDC-3,
blaPAO,
blaNDM-1		aac(3)-Id, aadA2,
aph(3′)-IIb		mutations in gyrA and parCColistin-resistant strain is confirmeddfrB5, fosA,
sul1,
tetG,
catB7, cmlA1
ST277blaSPM-1,
blaIMP-1,
blaOXA-56,
blaPAO		aacA1,
aacA4,
aac(6)-Ib,
aac(6)-Ib-cr, aph(3′)-IIb,
aadA7		mutations in gyrA and parCNo data availablefosA,
sul-1, catB7
ST357blaPER-1,
blaGES-5,
blaLCR-1,
blaIMP-1 variants,
blaVIM-2,
blaOXA-2 variants,
blaVEB1-like		aadA11,
aadA2,
aadB,
aacA3,
aacA4,
aph(3)-VIa, aac(6)-Ib, aph(6)-Id		mutations in gyrA and parCNo data availablefos1,
fosE,
sul-1
ST654blaKPC-2,
blaIMP-1,
blaVIM-2,
blaNDM-1		aacA4,
aacA5,
aadb		mutations in gyrA and parCNo data availablesul-1
ST773blaOXA-50-like variants,
blaVEB-1,
blaIMP-2,
blaPAO,
blaVIM-2,
blaNDM-1		rmtB,
aph(3′)-Iib,
aac(3)-Ia, aadA1,
aadB		qnrVC1,
mutations in gyrA and parC		Strains susceptible only to colistin are detectedfosA,
sul-1,
tetG,
catB7
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kocsis, B.; Gulyás, D.; Szabó, D. Diversity and Distribution of Resistance Markers in Pseudomonas aeruginosa International High-Risk Clones. Microorganisms 2021, 9, 359. https://doi.org/10.3390/microorganisms9020359

AMA Style

Kocsis B, Gulyás D, Szabó D. Diversity and Distribution of Resistance Markers in Pseudomonas aeruginosa International High-Risk Clones. Microorganisms. 2021; 9(2):359. https://doi.org/10.3390/microorganisms9020359

Chicago/Turabian Style

Kocsis, Béla, Dániel Gulyás, and Dóra Szabó. 2021. "Diversity and Distribution of Resistance Markers in Pseudomonas aeruginosa International High-Risk Clones" Microorganisms 9, no. 2: 359. https://doi.org/10.3390/microorganisms9020359

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop